Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Amplicor HPV test

This article was originally published in The Gray Sheet

Executive Summary

Roche study comparing Amplicor with Digene's Hybrid Capture 2 test suggests Amplicor may be more sensitive, according to Jane Gibson, PhD, molecular genetics director at the AmeriPath Center for Advanced Diagnostics in Orlando. Presented at the 21st International Papillomavirus Conference in Mexico City, the results reveal an HPV-positive rate of 15.1% with Amplicor and 9.3% with the HC2 test. The presence of high-risk HPV was confirmed in 33% of Amplicor positive/HC2 negative specimens. Roche plans to complete U.S. clinical trials of the polymerase-chain reaction test by Q2 2005 (1"The Gray Sheet" Feb. 9, 2004, p. 14)...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts